Janssen R&D Ireland (Janssen) have announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81...
Gilead's Single-Tablet "Quad" Regimen For HIV Achieves A High Rate Of Virologic Suppr
Gilead Sciences, Inc. (Nasdaq:GILD) announced Phase II clinical trial results showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada(R)...
Gilead's Single-Tablet "Quad" Regimen For HIV Achieves A High Rate Of Virologic Suppr
Gilead Sciences, Inc. (Nasdaq:GILD) announced Phase II clinical trial results showing that its investigational fixed-dose single-tablet "Quad" regimen of elvitegravir, GS 9350 (cobicistat) and Truvada(R)...